Clinical & Research
There are numerous clinical applications for HDVA. HDVA is being developed to help evaluate and manage various medical conditions, such as stroke, sleep apnea, vasospasm, head injury, hydrocephalus, cognitive impairment, dementia, and various metabolic disorders that may predispose to vascular disease. At present, HDVA is available only as part of a clinical protocol at select institutions or as part of a medical consultation with the physician-developers of HDVA.
Commercial
In studies of drugs or devices, HDVA expedites clinical trials with fewer subjects by 1) improving cohort heterogeneity, 2) elucidating disease and treatment mechanisms, and 3) providing physiological 'scalar' markers of clinical endpoints. HDVA is a sensitive, quantitative, low cost, non-invasive, safe way to measure the impact of therapies. Moreover, HDVA is a convenient measure that can be incorporated without significantly altering trial design.
HDVA has been applied most extensively to the study of cerebrovascular disease. These diseases constitute a set of conditions having cognitive impairment or stroke risk as a common feature.
Whereas imaging studies are not helpful for revealing the physiological changes that may be attributed to or explain cognitive impairment or stroke risk, physiological metrics have the potential to do so. HDVA has been demonstrated to be able to classify forms of cognitive impairment and is being developed as a potential diagnostic tool for the disease processes that are manifested as cognitive impairment.
With endovascular interventions, embolization is omnipresent and does not correlate with outcome, nevertheless these procedures are associated with stroke risk. HDVA defines the vascular states of vulnerability to emboli associated with endovascular procedures and may be used to improve safety and efficacy of transcatheter therapies. HDVA-defined states of vulnerability to stroke have also been defined in sleep apnea.
Scientific Research
We refer you to the Publications section of this web site.